Davita Inc vs Walmart Stores Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Walmart Stores Inc trades at $110.23 (market cap $877.15B). The key difference: Walmart Stores Inc is far larger — about 77.7× Davita Inc's market cap, and Walmart Stores Inc pays a 0.9% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Walmart Stores Inc for 101 Days on average.
| DVA | WMT | |
|---|---|---|
Market Cap | $11.29B | $877.15B |
Volume | 582,204 | 23,616,578 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $134.20 |
52-Week Low | $103.87 | $100.61 |
Typical Hold Time | 113 Days | 101 Days |
Enterprise Value | $24.01B | $939.38B |
Dividend Yield | — | 0.9% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Walmart (WMT) trades at $110.56, up 3.11% today, showing strong momentum after three consecutive quarterly earnings beats. The stock faces technical resistance near $110 with neutral indicators, while fundamentals reveal robust revenue growth to $681B (2025) and improving net margins to 2.85%. Recent news highlights expansion in AI capabilities, Marketplace growth exceeding 50%, and new Medicare Advantage partnerships, positioning Walmart for continued market share gains in the competitive retail sector.
Walmart presents a compelling long-term investment case with analyst consensus pointing to 16.5% upside to the $128.84 price target. However, the elevated P/E ratio of 39.2 and rising operational costs pose valuation and margin compression risks. Investors should weigh the company's digital transformation success against potential consumer spending pressures and inflationary headwinds affecting retail profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →